Gerresheimer AG (GXID.XC)
Cboe UK · EUR · Healthcare · Medical Instruments & Supplies
€28.09 (+0.00%) as of
Key statistics
- Market cap
- 970.23M
- EPS (TTM)
- -11.86
- Dividend yield
- 0.00%
- 52-week range
- 15.65 – 29.95
- Beta
- 0.45
- Revenue (TTM)
- 2.32B
- Profit margin
- -17.51%
- Volume
- 368.00
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. The company offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Düsseldorf, Germany
- Employees
- 13,301
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.